Introduction
X-inactivation clonality analysis is a clever application of Mary Lyon's fundamental observation that each X-chromosome in excess of one is randomly inactivated in cells of the developing female embryos. 1 The first clonality studies performed to investigate the nature of human neoplasms were done almost three decades ago, [2] [3] [4] and have opened a fertile field of investigation that has allowed investigators to unravel some of the basic tenets of modern oncology. The current decade has been particularly prolific with the largest number of clonality studies performed yet, and the accumulation of an unprecedented quantity of data. This can be primarily attributed to the development of newer, more informative clonality assays, which allow X-inactivation analysis to be performed in the majority of females. Although the new information has sometimes confirmed and sometimes contradicted earlier conclusions, it has mainly opened many novel avenues of investigation in cancer biology and hematopoiesis.
In this paper, we will review the recent progress made in X-inactivation techniques, in the etiology of nonrandom Xinactivation occurring in the normal population, and in the study of human neoplasms. We will outline the questions and potential problems that should be addressed in the next decade.
The development of newer, more informative Xinactivation-based clonality assays
The applicability of X-inactivation analysis has been mainly limited by intrinsic properties of the methods used to determine X-inactivation ratios in females. The electrophoretic analysis of the glucose-6-phosphate dehydrogenase isoenzymes (G6PD) used by Fialkow and coworkers 5 was limited by a low level of informativeness in the general population, which effectively precluded analysis of rare disorders, analysis of large cohorts of females, and familial analysis. In the mid 1980s, informativeness was improved by the identification of DNA polymorphisms linked to residues differentially methylated between the active and inactive X-chromosome. 6 The informativeness was increased but still insufficient to allow general applicability. An important recent contribution to the field of Xinactivation analysis has been the identification by Allen et al 7 of differential methylation sites between the active (Xa) and inactive X (Xi) chromosome closely linked to the multiallelic CAG short tandem repeat 8 (STR) of the first exon of the human androgen-receptor gene (AR or HUMARA; GenBank M21748 JO4150). The AR CAG repeat is polymorphic in 90% of females of all racial groups 9 rendering X-inactivation analysis feasible in the majority of females with a single assay. The HUMARA assay has already been validated by several investigators [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and found to be reliable and reproducible to study human neoplasia. The high informativeness of this PCR-based assay coupled with the ability to precisely quantitate allelic ratios have allowed for the analysis of rare diseases such as Langerhans' cell histiocytoses 20 (LCH) and juvenile myelomonocytic leukemia 21 (JMML), and the analysis of a large cohort of normal females to investigate the incidence of nonrandom X-inactivation. 22 Furthermore, it has been possible to analyze X-inactivation pattern in families to investigate heritability of skewed patterns of X-inactivation. 23 The HUMARA assay is currently the most frequently utilized method of Xinactivation analysis by most investigators.
Another important improvement has been the development of several clonality assays based on transcriptional analysis of coding polymorphisms. Prchal et al 24, 25 have been instrumental in developing such assays. One of these new assays takes advantage of a more frequent polymorphisms at the G6PD locus (C/T1311) which can be analyzed by reverse transcription followed by ligase detection reaction. A second informative coding polymorphism has been identified in the palmitoylated membrane protein p55 (G/T at cDNA 358). When both assays are used, heterozygosity of close to 50% is expected. 26 Another coding polymorphism located in the iduronate-2-sulfatase (IDS) gene (C/T 438) 27 has also proven to be useful in the study of clonal hematopoietic disorders. 28 Although these assays are substantially less informative than the HUMARA assay, they have the theoretical advantage of not relying on methylation pattern to assess the activity of the X-chromosome, since they directly rely on the exclusive transcriptional activity of the active X-chromosome.
Study of the normal female population: unequal Lyonization revisited
Incidence of nonrandom X-inactivation (NRXI) in the normal population Unequal Lyonization, which is most appropriately termed nonrandom X-inactivation (NRXI), is said to occur when there is a significant deviation from the theoretical 1:1 ratio between the paternal (Xp) and maternal (Xm) X-chromosome in healthy females. Although criteria for NRXI are arbitrary, an allelic Review L Busque and DG Gilliland 129 ratio у3:1 (which corresponds to the expression of 75% of one allele) has been widely accepted in the literature. 13, 22, [29] [30] [31] [32] Determination of the incidence of NRXI should be straightforward since it can be simply estimated by using X-inactivation assays in healthy females. Surprisingly, data obtained in the last 20 years by different investigators have been contradictory. Vogelstein et al 32 found only three out of 81 (3.7%) normal females to have NRXI using the phosphoglycerate kinase (PGK) and hypoxanthine phosphoribosyl transferase (HPRT) Xinactivation probes. Recently, Gale et al 29 found significant NRXI in blood-derived cells in 23% of normal females using PGK and HPRT probes and 22% of females using M27␤, 30 which has been confirmed in numerous other studies. [33] [34] [35] [36] Discordance in the incidence of NRXI was initially explained by the diversity of assays used, the different criteria for NRXI, and the small population sizes. However, a more plausible explanation came from studies that analyzed Xinactivation patterns of different tissues in the same female. For example, Fey et al 33 reported that the incidence of NRXI was low in gastrointestinal mucosa and thyroid tissue, but was significantly higher in blood cells. Gale et al 31 reported that 45% of females analyzed have different patterns of X-inactivation when blood-derived cells were compared to muscle and skin samples. Interestingly, blood cells in both studies were more frequently skewed than other tissues. These studies suggested that X-inactivation patterns were tissue-specific. One explanation for specificity of the X-inactivation patterns was elucidated by the direct analysis of X-inactivation using the X-linked lacZ transgene, which is subjected to inactivation and consequent loss of ␤-galactosidase activity in mouse embryos. These studies showed that X-inactivation proceeds with different schedules in different somatic tissues. 37 The second, and perhaps most important clue to the discrepancy in incidence of NRXI came with the analysis of Xinactivation patterns in females of different age groups. An age difference in NRXI was first suggested by Fey et al 38 who reported a higher incidence of skewing in older females compared to children. We characterized the effect of age on NRXI in a large cross-sectional study in which the X-inactivation ratios were determined with the HUMARA assay in 295 normal females from three age groups: (1) neonates; (2) 28-32 years old; and (3) age greater than 60 years. We documented an incidence of skewing (ratio у3:1) of 8.6% in neonates, 16 .4% in the 28 to 32 years and 37.9% in women greater than 60 years (P Ͻ 0.0001 vs neonates, P = 0.064 vs 28 to 32 years) (Figure 1) . 22, 39 The different incidence of skewing between the neonates and the 30-year-old group was not statistically significant. This suggests that skewing found in normal neonates probably correspond to true NRXI occurring during the embryological process of X-inactivation, and that skewing found in older females is likely to be caused by other mechanisms (vide infra). These results have subsequently been confirmed by other investigators. [40] [41] [42] Since the incidence of skewing may vary more than fourfold depending on the age of the population, it is clear that the age of the cohort analyzed may constitute the major confounding factor explaining the discrepancy of previous studies.
The etiology of nonrandom X-inactivation (NRXI) in the normal population Primary nonrandom X-inactivation:
The cause of NRXI has been more difficult to investigate than its incidence. Cur-
Figure 1
Incidence of nonrandom X-inactivation (NRXI) in blood cells (allelic ratio у3:1) of normal females from three different age groups. The incidence of NRXI is 37.9% in females aged more than 60 years and statistically different from the 30 years (P Ͻ 0.0064) and from the neonate group (P Ͻ 0.0001) (from Busque L et al 22 ).
rently, NRXI occurring in normal females is thought to be related to the limited number of cells present at the time of random X-inactivation during embryogenesis. 5, 29 In this model, the variance of the distribution of X-inactivation patterns in females follows a binomial distribution where the deviation from the mean is inversely proportional to the number of cells present at the time of X-inactivation. For example, if the inactivation occurs when there are only four cells present, the incidence of skewing (ratio у3:1) will be 37%. If inactivation occurs at the 16 cell stage, the incidence of skewing will be 5%. 43 In contrast to humans, NRXI has been shown to be genetically controlled in murine species. Cattanach et al 44 demonstrated that the different alleles of a gene called Xce (X-chromosome controlling element) can bias the choice of the X to be inactivated. Xce has three well characterized alleles which can be classified as a gradient of strength: Xce c Ͼ Xce b Ͼ Xce a . 45 The heterozygotes exhibit NRXI. Xce maps within or in the vicinity of the Xic (X-chromosome inactivation center), 46 and it has been shown biochemically 45 and cytologically 47 to cause primary NRXI rather than secondary cell selection. Furthermore, the effects of different Xce alleles can modify the imprinted preferential inactivation of Xp in extraembryonic tissue. 48 The investigation of heritability of NRXI in humans has been precluded by the low informativeness of most assays. The multiple alleles of the STR at the AR locus has allowed for the evaluation of the transmission of skewed patterns of Xinactivation in families. Naumova et al 23 have reported a family where all seven daughters had highly skewed patterns of X-inactivation with preferential activation of the paternal Xchromosome. Furthermore, the paternal grandmother also showed a skewed pattern of X-inactivation with the same Xchromosome preferentially activated. These results suggested an X-linked transmission of NRXI in this family. Pegoraro et al 49 reported a high incidence of NRXI in a family and localized the genetic anomaly responsible for the trait to the Xq28 region using linkage analysis. They further demonstrated that affected individuals have a large segment of DNA deleted in the Xq28 region. 49 Further evidence for a genetic cause of NRXI came with the recent work by Plenge et al 50 who documented a rare cytosine to guanine mutation in the XIST (X-inactivation specific transcript) minimal promoter in nine females of two different families that all showed preferential inactivation of the X chromosome carrying the mutation.
Although the data cited above clearly indicate that NRXI may be genetically determined and transmissible in some families, it does not rule out a stochastic cause of NRXI for the vast majority of females. To evaluate the possibility of heritability of NRXI in the general population of females, we have analyzed the relationship between the degree of NRXI in 177 mother-daughter (neonates) pairs, of which 142 were both heterozygous at the AR locus. The allelic ratio between the two X-linked alleles at the AR locus was determined for each individual. Allelic ratios for the neonatal population were scored into two categories: skewed (ratio у3, n = 17) or nonskewed (ratio Ͻ3, n = 125). Of the 17 skewed neonates, 10 (58.8%) had mothers that were also skewed. In contrast, of the 125 non-skewed neonates, only 26 (20.8%) had mothers that were skewed (P = 0.0018, Fisher's exact test, two-tail) (R Mio and L Busque, 1997 submitted).
These data, taken together, support the hypothesis that NRXI may be due not only to the stochastic process of Xinactivation occurring in a limited number of cells, but that one or several genes may bias the choice of which X is to be inactivated during the embryological process of Xinactivation. Further studies should be aimed at identifying the genetic elements responsible for NRXI.
Acquired skewing in blood cells with aging:
The increased incidence of nonrandom X-inactivation ratios found in blood cells of the female elderly population, termed acquired skewing, may be caused by a completely different mechanism than NRXI documented in neonates. Several hypotheses may explain the acquired skewing phenomenon. First, it is possible that acquired skewing truly corresponds to clonal hematopoiesis caused by somatic mutation(s) in hematopoietic stem cell(s) conferring a growth advantage to the mutated cell(s). An argument in favor of this possibility is that the incidence of hematological malignancies increases significantly with age. Age-related incidence is particularly striking for diseases such as myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) with a peak incidence after 65 years of age. [51] [52] [53] However, the incidence of 40% of skewing in the normal population in this age group would argue against any pathological association, since even the most common hematologic malignancies have incidences less than 0.01%. Another hypothesis is that acquired skewing is a reflection of stochastic clonal dominance secondary to significant stem cell depletion with age in normal females. If this hypothesis is applied to the acquired skewing in normal females observed in our study, it would suggest that 40% of the normal females have a severe reduction in the number of their stem cells. A third possibility is that the skewing phenomenon is a genetic trait caused by a gene which resides on one of the two Xchromosomes. In contrast to the gene involved in primary NRXI, this gene would not bias the choice of which X-chromosome is to be inactivated, but instead would provide a selective growth advantage to hematopoietic cells that have this gene on the active X-chromosome. If the growth advantage is slight, it may take years for the population of cells with this gene in the active state to completely dominate the marrow. In this circumstance, all cells would have the same X in the active state and will show a completely skewed pattern of X-inactivation compatible with the acquired skewing phenomenon. In this model, the cells would originate from numerous different progenitors, and therefore would be polyclonally derived. The hypothesis of a human X-linked gene affecting the growth of hematopoietic cells was first suggested by Luzzato et al. 54 Convincing recent evidence for such a genetically determined positive growth selection advantage has been provided by Abkowitz et al 55 through X-inactivation analysis at the G6PD locus of Safari cats (F1 generation of Goeffroy (G) and Domestic (d) cats). Balanced hematopoiesis was documented between the G and d alleles in the first year of life of the heterozygous cats, but most of these animals demonstrated skewed patterns of X-inactivation in blood-derived cells with aging. These results are identical to the acquired skewing phenomenon found in humans. The intrinsic qualities of the model developed by Abkowitz et al has made it possible to distinguish between a stochastic and a genetically controlled cause of skewing. Since no recombination is possible between the two Xs of the Goeffroy and Domestic cats, the Safari cats have half their cells with the G X-chromosome active and half with the d X-chromosome active. If the cause of the skewing phenomenon is stochastic (clonal hematopoiesis or stem cell depletion) there is as much chance for the phenomenon to occur in G or in d cells, and consequently there should be as many cats skewed in favor of the G allele as cats skewed for the d allele. All the cats studied by Abkowitz et al showed a predominant G allele, which provides persuasive evidence that the acquired skewing is genetically determined, rather than stochastic. Furthermore, these data indicate that the skewing gene must be localized to the X-chromosome, otherwise no skewing could be observed. The fact that in the initial phase of hematopoiesis, X-inactivation was balanced between the G and the d alleles also eliminates primary NRXI (embryological) as a cause of skewing. The mechanism would be the opposite of the one described for skewing that occurs in females heterozygous for X-linked disease genes (reviewed in Ref. 56 ). In these rare females, the cells that harbor the mutant X in the active state are selected against.
Study of human neoplasia
The availability of more informative tests for clonality assessment such as the HUMARA assay has allowed for analysis of numerous cancers including hematologic malignancies and several solid tumors with benign and malignant behavior. It has also been possible to analyze reactive disorders, nononcologic conditions such as nodular hyperplasia of liver, 57 and even atherosclerosis 58 (Table 1 ). We will provide a brief overview of several recent findings.
The distinction between polyclonality and clonality is fundamental to the pathophysiology of any disease process. Clonality infers selective growth advantage caused by acquired somatic mutation occurring in a single progenitor cell. Field effect, viral infection, stimulation by cytokines may cause polyclonal growth of cells. Documentation of clonality may orient research toward the identification of specific mutations causing the disease. X-inactivation analysis has recently allowed for the elucidation of the clonal nature of several enigmatic disorders. One such disease is Langerhans' cell histiocytoses (LCH) which was considered by many as a noncancerous reactive disorder. 59 LCH had eluded clonality investigation in the past because of its relative rarity, the absence of a specific marker allowing to distinguish the lesional histiocytes from reactive cells, and the difficulty of analyzing a pure population of cells. The high informativeness of the HUMARA assay coupled with the ability to measure precisely X-inacti- vation ratios has demonstrated that LCH is a clonal proliferative disorder of CD1a cells. This has been shown directly by the analysis of CD1a flow sorted cells 60 and indirectly by the analysis of tissue infiltrated by lesional CD1a cells. 20 Similarly, juvenile myelomonocytic leukemia (JMML) 61 which was thought possibly to reflect polyclonal proliferation of hematopoietic cells with increased sensitivity to GM-CSF, has only recently been shown to be the result of clonal proliferation of early stem cell progenitors by the analysis of clonality at the AR, PGK and G6PD loci. 21 Other examples of diseases where monoclonality was documented in situations where polyclonality was expected include: (1) Focal nodular hyperplasia of the liver (FNH), a benign hepatic lesion composed of an encapsulated multinodular proliferation of normal appearing hepatocytes, has been shown to result from clonal proliferation of hepatocytes using the HUMARA assay. 57 (2) It has been documented that the atherosclerotic plaque that occurs in coronary arteries is comprised of clonally derived smooth Review L Busque and DG Gilliland 132 muscle cells. 58 In the latter situation, it is possible that the unexpected clonality is the consequence of the proliferation of several smooth muscle progenitor cells originating from a small region or patch of the artery where all cells have the same pattern of X-inactivation. In contrast to the examples cited above, it has also been possible to demonstrate that some diseases of expected monoclonality have been shown to be polyclonally derived. One such disease is the medullary carcinoma of the thyroid gland in multiple endocrine neoplasia type 2, which has been shown to be polyclonally derived in the majority of cases including sporadic and hereditary forms. 62 It is also interesting to note that Rosai-Dorfman's disease, or histiocytosis with massive lymphadenopathy, which shows several similarities to LCH has been shown to be caused by polyclonal proliferation of cells, implying that this disease has a different pathogenesis than LCH. 63 X-inactivation analysis also has the unique capacity to investigate the cellular origin of multicentric neoplasms. Do all disseminated tumors of a particular cancer originate from a single mutant progenitor cell? Or, do they arise synchronously from independent mutated cells? This distinction is fundamental to our understanding of the mechanism of tumor metastasis, and to the documentation of a potential field effect in certain cancers. One recent study was aimed at resolving this issue for multicentric Kaposi's sarcoma lesions. The clonality analysis at the AR locus documented that skin lesions of Kaposi's sarcoma were clonally derived. 64 It was further documented that multiple lesions in the same individual had the same pattern of X-inactivation. These data are consistent with a single cell origin for Kaposi's sarcoma, and suggesting that the mutation(s) giving rise to the cellular growth advantage occurred prior to systemic dissemination of Kaposi's sarcoma. 64 In contrast to the situation of Kaposi's sarcoma, Marshal et al 65 documented that multiple uterine leiomyomata were clonally derived but that the different 'tumorlets' in an individual did not have the same X-chromosome in the active state, arguing for an independent origin of each tumor. 65 Xinactivation analysis has also been proven useful to investigate the pathogenesis of tumors composed of different cell types. Zhu et al 66 investigated rare tumors of the central nervous system composed of glial and neuronal components called gangliogliomas. Using both DNA and RNA-based 10 clonality determination at the AR locus, they have shown gangliogliomas to be clonally derived and that both cellular components probably originate from a common mutated progenitor.
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These novel findings on clonality have promoted a reevaluation of our understanding of the relationship between clonality and malignancy. One major contribution of X-inactivation analysis during the past 30 years has been the documentation that almost all cancers are clonal and that clonality is intimately related to malignancy. However, one of the lessons of the last decade has been that a skewed pattern of Xinactivation does not automatically indicate clonal derivation of cells, as there are many other causes of skewing in the normal population (Table 2) . Furthermore, the documentation of clonal derivation of cells, in the presence of appropriate somatic controls, does not necessarily indicate a malignant process. Even if clonality is a first step toward the progression to a malignant phenotype, some clonal proliferations of cells apparently have no transformation potential. Malignancy perhaps relates more to the biologic behavior of a population of cells in relation to the host, than to the clonal derivation of cells. It is clear that several clonal proliferative disorders are quite indolent and should perhaps not be considered as true Table 2 Causes of nonrandom X-inactivation in normal females (excluding clonal proliferative disorders) 59 with indolent clinical courses, such as eosinophilic granuloma of bone, should not necessarily be influenced by the recent documentation that these are clonal proliferative disorders. The relationship between clonality and malignancy may also be evaluated in clinical settings where prospective evaluation of clonality is feasible. Fortunately, clinical settings where there is a subgroup of normal females with a sufficiently high risk of developing hematologic cancer to allow a prospective analysis of samples are rare. However, female patients with lymphoma treated with autologous bone marrow transplantation (ABMT) may constitute one such high-risk group, and offer a rare opportunity to study prospectively the development of clonal hematopoiesis and future malignant transformation. It has been recently shown that this cohort of patients have an incidence of developing a myelodysplastic syndrome or leukemia as high as 18% within 6 years of transplant. 67 Prospective analysis of blood samples from this patient population has demonstrated clonal hematopoiesis precedes and predicts the development of MDS. 68 These data also confirm the multistep pathogenesis of secondary leukemia. Analysis of sequential samples for candidate oncogenes or tumor suppressor genes may allow for identification of genes which are involved in each step of the progression from clonal hematopoiesis to malignant transformation.
The future of X-inactivation analysis
What is the role of X-inactivation clonality analysis in the next decade? X-inactivation clonality analysis will continue to be an important adjuct to the molecular biology of human neoplasia and can be used to address a spectrum of problems, including polyclonal vs monoclonal origins of cells. Clonality analysis has evolved in the last decade as a powerful means of investigating disease pathophysiology that is no longer limited to the field of oncology. The biology of hematopoiesis, the mechanism of X-inactivation, and the characterization of genetic changes in relation to clonality development are new avenues of investigation that need to be explored by Xinactivation.
There are several important issues that should be addressed by X-inactivation analysis in the next decade. (1) Clonality assays: extensive validation of the third generation assays to precisely delineate their limits and pitfalls. Large cohorts of normal and females with known clonal disorders should be analyzed with HUMARA and transcriptional assay such as the G6PD, p55 and IDS. (2) Nonrandom X-inactivation (embryological): the potential existence of a human equivalent to the murine Xce locus that would be responsible for NRXI should be investigated by linkage analysis in families. The identification of alleles of different strength that bias the choice of which X is to be inactivated during embryogenesis would allow, for the first time, the distinction between NRXI from clonal derivation of cells in the absence of any specific somatic control tissue. (3) Acquired skewing in blood cells of elderly females: the cause of acquired skewing in normal females should be investigated since this may give an important insight on the biology of the aging hematopoietic tissue and possibly in the biology of age-associated hematological malignancy. The acquired skewing phenomenon may provide unique insights into the biology of hematopoiesis in humans. (4) Study of human neoplasia: X-inactivation assays should be used as molecular markers of disease progression and help define the genetic events responsible for acquisition of a cellular growth advantage, and which other genetic alterations are responsible for the transformation toward a full malignant phenotype. X-inactivation analysis is essential to the elucidation of the multistep pathogenesis of cancer. Finally, application of clonality analysis to disease processes thought to be polyclonal such as artherogenesis, may yield further surprises and insights into pathophysiology of these diseases. (5) Diagnostic applications of X-inactivation clonality assays: the recent accumulation of data should allow us to devise clinical application of such assays in the near future. The possibility of diagnosing a clonal population of cells in any tissue in most females would be a tremendous breakthrough for woman's health. The extensive validation of assays, a better understanding of the causes of skewing in normal females and in depth understanding of the biology of clonal proliferative disorders are prerequisites to the applicability of X-inactivation assays in the clinical setting.
Conclusions
It has been nearly three decades since Fialkow harnessed an extraordinary source of insight into the pathophysiology of human neoplasia through analysis of X-chromosome inactivation. Only rarely does one individual open a field of scientific inquiry that provides so many seminal insights into such a broad spectrum of human disease processes. His work has opened fertile new venues for investigation, and will remain the foundation for our understanding of the clonal proliferation nature of human cancers. Dr Fialkow has provided the shoulders for us to stand on. In his memory, we will hope to catch a glimpse of the horizon.
